Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Assets Average: 2020-2025

Historic Assets Average for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $940.1 million.

  • Apellis Pharmaceuticals' Assets Average rose 4.08% to $940.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $940.1 million, marking a year-over-year increase of 4.08%. This contributed to the annual value of $836.9 million for FY2024, which is 8.06% up from last year.
  • According to the latest figures from Q3 2025, Apellis Pharmaceuticals' Assets Average is $940.1 million, which was up 15.44% from $814.3 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Assets Average ranged from a high of $1.1 billion in Q2 2022 and a low of $612.8 million during Q3 2021.
  • Moreover, its 3-year median value for Assets Average was $868.2 million (2024), whereas its average is $869.4 million.
  • Its Assets Average has fluctuated over the past 5 years, first declined by 25.20% in 2021, then soared by 53.02% in 2022.
  • Over the past 5 years, Apellis Pharmaceuticals' Assets Average (Quarterly) stood at $703.7 million in 2021, then rose by 16.03% to $816.6 million in 2022, then fell by 1.60% to $803.5 million in 2023, then grew by 11.20% to $893.5 million in 2024, then rose by 4.08% to $940.1 million in 2025.
  • Its Assets Average was $940.1 million in Q3 2025, compared to $814.3 million in Q2 2025 and $846.2 million in Q1 2025.